Pricing
Volume for CROs, self-serve for biotech.
Honest tiers grounded in the real unit economics of a feasibility run. CROs run on a platform plan — volume, white-label, dedicated-cluster, PO/invoice. Biotech and academic teams start per-study. No per-seat pricing.
Per-study, annual, and CRO platform tiers.
CRO Platform
Volume pricing scoped to your bid pipeline
For CROs running feasibility across many sponsors and protocols. Resell cited verdicts under your own brand, run in your own cloud, and call the engine straight from your bid-defense pipeline.
- White-label verdicts & dedicated-cluster mode
- Volume API / MCP throughput, batch submission
- Per-program isolation + Part 11 audit export
- PO and invoice billing — no card required
For biotech & academic teams
Per-study
For low-volume and academic teams running the occasional feasibility check. Pay for the protocols you actually analyse — nothing else.
- One cited feasibility verdict per protocol
- PTRS, site density, budget envelope, cohort reachability
- Full citation trail + Part 11 audit record
- Price scales with indication and analysis depth
Biotech Starter
Most popularFor a biotech running feasibility as a regular part of trial planning. Roughly twelve analyses a year at a predictable annual rate.
- ~12 feasibility analyses included per year
- Everything in Per-study, billed annually
- API and MCP access for your own pipelines
- Email support and onboarding
Biotech Pro
For teams that want feasibility on tap across a growing pipeline — run as many protocols as you need without metering each one.
- Unlimited feasibility analyses
- Priority API / MCP throughput
- Audit-retention support for regulatory filings
- Direct line to the team during planning cycles
No per-seat pricing. CROs and larger sponsors run on the CRO Platform plan — white-label, dedicated-cluster, and PO/invoice billing. Annual and platform plans support purchase-order and invoice payment; per-study runs can be paid by card.
A few honest notes
How we think about price
We are looking for design partners, not logos. If you are an early biotech willing to run real protocols and tell us where the verdict is wrong, the per-study range bends toward the bottom — and your feedback shapes the roadmap.
Annual plans are sized to real usage. Biotech Starter assumes about a protocol a month; Biotech Pro removes the meter entirely for teams analysing across a pipeline. If your volume sits between them, we will quote the honest middle rather than push you up a tier.
Pricing here is indicative. Final numbers depend on indication complexity, analysis depth, and deployment model. We would rather scope it with you than hide it behind a sales motion.
See a verdict you can actually check.
Send us a protocol. We'll return a fully cited feasibility verdict you can trace, line by line, back to public data — yours to white-label, defend in a bid, or hand to a regulator.